Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
暂无分享,去创建一个
C C Schulman | A. Zlotta | M. Remzi | M. Marberger | B. Djavan | M Remzi | B Djavan | C. Schulman | A Zlotta | K Ghawidel | A Basharkhah | M Marberger | A. Basharkhah | K. Ghawidel | M. Marberger | Claude C. Schulman
[1] E. Leifer,et al. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. , 1996, Urology.
[2] W. Catalona,et al. Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.
[3] J. Oesterling,et al. Prostate-specific antigen density. , 1997, The Urologic clinics of North America.
[4] C C Schulman,et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. , 1999, Urology.
[5] W. Fair,et al. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. , 1997, The Journal of urology.
[6] J. Oesterling,et al. Age-specific reference ranges for serum prostate-specific antigen. , 1995, The Canadian journal of urology.
[7] G. Durkan,et al. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? , 1999, BJU international.
[8] J. Oesterling,et al. Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing. , 1998, Urology.
[9] O. Nakashima,et al. Necessity of repeat biopsies in men for suspected prostate cancer , 1999, International journal of urology : official journal of the Japanese Urological Association.
[10] J. Oesterling,et al. The clinical usefulness of prostate specific antigen: update 1994. , 1994, The Journal of urology.
[11] H. Klocker,et al. Improvement of specificity in PSA‐based screening by using PSA‐transition zone density and percent free PSA in addition to total PSA levels , 1998, The Prostate.
[12] Entezari,et al. The importance of measuring the prostatic transition zone: an anatomical and radiological study , 1999, BJU international.
[13] W. Catalona,et al. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.
[14] W. Catalona,et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. , 1996, The Journal of urology.
[15] C C Schulman,et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. , 1998, The Journal of urology.
[16] M M Elhilali,et al. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. , 1994, Urology.
[17] M. Marberger,et al. Transition zone volume on transrectal ultrasonography is more accurate and reproducible than the total prostate volume , 1997 .
[18] T. Stamey,et al. Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .
[19] M. Brawer,et al. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. , 1998, The Journal of urology.
[20] B. G. Blijenberg,et al. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population , 1998 .
[21] J. Beiser,et al. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. , 1997, The Journal of urology.
[22] P. Schellhammer,et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. , 1997, Urology.
[23] H. Carter,et al. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. , 1997, The Urologic clinics of North America.
[24] M. Brawer. Prostate-specific antigen: Critical issues , 1994 .
[25] J. Morote,et al. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. , 1997, The Journal of urology.
[26] W. Catalona,et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.
[27] R. Babaian,et al. Role of PSA and its indices in determining the need for repeat prostate biopsies. , 1997, Urology.
[28] W. Catalona,et al. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. , 1995, The Journal of urology.
[29] Jerome P. Richie,et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.
[30] A. Zlotta,et al. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? , 1999, Urology.
[31] Fritz H. Schröder,et al. Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer , 1998 .
[32] C. Bangma,et al. Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. , 1998, The Journal of urology.